GeneMatrix Inc (109820) Fair Value & Analysis
Healthcare · KR · Market cap 32.9B KRW
Fair value as of: Jun 25, 2026
Analysis
GeneMatrix Inc (109820) currently trades at 1,459 KRW, while our model-based Fair Value estimate is 731.57 KRW — implying the stock looks roughly 49.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also provides biochemical diagnostics, such as special chemistry and general chemistry, that includes semi and full auto analyer, and calibrators and controls. The company was founded in 2000 and is headquartered in Seongnam-si, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is GeneMatrix Inc (109820) undervalued?
What is the fair value of 109820?
What is the quality score of 109820?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.